Dossier
big pharma M&A
Coverage of big pharma M&A in the Nexus archive.
- Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech IPOs are gaining momentum while big pharmaceutical companies drive M&A activity to replenish drug pipelines before major patent expirations later this decade.